| 臺大學術典藏 |
2019-03-04T08:13:58Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin, Shu Yung;Yang, Ching Yao;Bin-Chi Liao;Chao-Chi Ho;Wei-Yu Liao;Chen, Kuan-Yu;Tsai, Tzu Hsiu;Chia-Lin Hsu;Hsu, Wei Hsun;Kang-Yi Su;Yih-Leong Chang;Lee, Jih Hsiang;Lin, Chia Chi;Jin-Yuan Shih;Yang, James Chih Hsin;Chong-Jen Yu; Lin, Shu Yung; Yang, Ching Yao; BIN-CHI LIAO; CHAO-CHI HO; WEI-YU LIAO; Chen, Kuan-Yu; Tsai, Tzu Hsiu; CHIA-LIN HSU; Hsu, Wei Hsun; KANG-YI SU; YIH-LEONG CHANG; Lee, Jih Hsiang; Lin, Chia Chi; JIN-YUAN SHIH; Yang, James Chih Hsin; Chong-Jen Yu |
| 臺大學術典藏 |
2020-03-06T05:26:04Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Yih-Leong Chang;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:57Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Kang-Yi Su;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; KANG-YI SU; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:09:08Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Wei-Yu Liao;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; WEI-YU LIAO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:25:17Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Liao W.-Y.; Ho C.-C.; Liao B.-C.; Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tzu-Hsiu Tsai;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Yang J.C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; TZU-HSIU TSAI; Chen K.-Y. |
| 臺大學術典藏 |
2020-07-21T06:46:21Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; Tsai T.-H.; Chen K.-Y.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Yu C.-J.; Yang J.C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:41Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Chao-Chi Ho;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yang J.C.; Yu C.-J.; JIN-YUAN SHIH; Lin C.-C.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Chen K.-Y.; Liao W.-Y.; Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C; Yu C.-J. |
| 臺大學術典藏 |
2018 |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Chia-Lin Hsu;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T02:38:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Anonymous |
| 臺大學術典藏 |
2021-07-13T06:04:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; LEE JIH-HSIANG; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; BIN-CHI LIAO; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-31T03:33:45Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
SHU-YUNG LIN; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:54Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; KUAN-YU CHEN; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T07:00:05Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; CHONG-JEN YU |
| 臺大學術典藏 |
2021-05-17T06:30:09Z |
Tumor promoter phorbol ester reversibly modulates tyrosine dephosphorylation/inactivation of protein kinase FA/GSK-3 alpha in A431 cells
|
Shiaw-Der Yang; Jau-Song Yu; Zin-Der Wen |
| 中山醫學大學 |
1998 |
Tumor promoting effect of N-nitroso-N-(2-hexanonyl)-3'-nitrotyramine (a nitrosated Maillard reaction product) in benzo(a)pyrene-initiated mouse skin carcinogenesis.
|
Tseng, TH; Chang, MC; Hsu, JD; Lee, MJ; Hsu, CL; Lan, KP; Wang, CJ |
| 國家衛生研究院 |
2024-06-17 |
Tumor promoting effect of PDLIM2 downregulation involves mitochondrial ROS, oncometabolite accumulations and HIF-1alpha activation
|
Yang, JX;Chuang, YC;Tseng, JC;Liu, YL;Lai, CY;Lee, AYL;Huang, CYF;Hong, YR;Chuang, TH |
| 中山醫學大學 |
1998 |
Tumor promotion in mouse skin by N-nitroso-N-(2-hexanonyl)-3’-nityrotyramine (a nitrosated Maillard reaction product)
|
Wang, Chau-Jong |
| 中山醫學大學 |
2000 |
Tumor promotion of N-nitroso-N-(3-keto-1, 2-butanediol)-3'-nitrotyramine derived from nitrosation of Maillard reaction product in CD-1 mice.
|
Chang, WC; Chen, CC; Tseng, TH; Huang, HP; Hsu, JD; Wang, CJ |
| 國立臺灣大學 |
2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu, Yi-Long; Fukuoka, Masahiro; Mok, Tony S. K.; Saijo, Nagahiro; Thongprasert, Sumitra; Yang, James C. H.; Chu, Da-Tong; Yang, Jin-Ji; Rukazenkov, Yuri; 楊志新 |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu Y.-L;Fukuoka M;Mok T.S.K;Saijo N;Thongprasert S;Chih-Hsin Yang;Chu D.-T;Chih-Hsin Yang;Rukazenkov Y.; Wu Y.-L; Fukuoka M; Mok T.S.K; Saijo N; Thongprasert S; CHIH-HSIN YANG; Chu D.-T; CHIH-HSIN YANG; Rukazenkov Y. |
